Internal Medicine, Rheumatology · Tujunga, CA
NPI
1437178274
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
6673 Foothill Blvd
Tujunga, CA, 91042
Phone (818) 265-2250
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
39,719 services
Medicare patients, 2024
830
Average age 73
Drug cost, 2024
$5.6M
9,737 prescriptions
Company payments, 2025
$5,096
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Dan T la was code J0129 (injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 12,425 times for 17 patients. In total Dan T la billed 39,719 services in 35 codes, and Medicare paid $1.1M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-08-14.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 12,425 | 17 | $33.90 | $421K |
| J0897 Injection, denosumab, 1 mg | Office | 6,720 | 65 | $20.63 | $139K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,980 | 61 | $0.10 | $205 |
| 99214 Office E&M - Established | Office | 1,954 | 722 | $105.39 | $206K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,618 | 685 | $13.30 | $22K |
| 99233 Hospital E&M - Subsequent | Facility | 437 | 66 | $98.17 | $43K |
| 96401 Chemotherapy Administration | Office | 378 | 149 | $62.91 | $24K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 364 | 54 | $0.77 | $280 |
| 20611 Joint Injection | Office | 336 | 107 | $85.81 | $29K |
| 96415 Chemotherapy Administration | Office | 306 | 40 | $24.59 | $7,523 |
| 96413 Chemotherapy Administration | Office | 261 | 40 | $116.15 | $30K |
| J7321 Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | Office | 217 | 40 | $57.28 | $12K |
| 99204 Office E&M - New | Office | 112 | 112 | $135.67 | $15K |
| 99232 Hospital E&M - Subsequent | Facility | 103 | 12 | $65.29 | $6,725 |
| 99223 Hospital E&M - Initial | Facility | 77 | 67 | $143.23 | $11K |
By year: 2022 $1.0M for 37,152 services; 2023 $1.2M for 47,487 services; 2024 $1.1M for 39,719 services.
Medicare prescription drug claims, 2024
In 2024, the drug Dan T la prescribed most often to Medicare patients was Gabapentin, with 953 prescriptions and refills. In total Dan T la wrote 9,737 Medicare prescriptions that cost $5.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 953 | 1,132 | 167 | $6,189 |
| Methotrexate Methotrexate Sodium | 851 | 1,172 | 131 | $12K |
| Hydroxychloroquine Sulfate Generic | 828 | 1,270 | 167 | $21K |
| Tramadol Hcl Generic | 757 | 762 | 186 | $2,776 |
| Prednisone Generic | 536 | 605 | 108 | $1,682 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 475 | 478 | 91 | $8,723 |
| Meloxicam Generic | 428 | 478 | 80 | $795 |
| Ibuprofen Generic | 372 | 398 | 90 | $2,155 |
| Diclofenac Sodium Generic | 330 | 357 | 83 | $69K |
| Allopurinol Generic | 262 | 504 | 66 | $1,732 |
| Prolia Denosumab | 238 | 1,405 | 143 | $397K |
| Alendronate Sodium Generic | 207 | 335 | 51 | $906 |
| Cyclobenzaprine Hcl Generic | 182 | 205 | 52 | $851 |
| Baclofen Generic | 162 | 218 | 38 | $1,261 |
| Celecoxib Generic | 160 | 176 | 34 | $3,587 |
Brand drugs: 1,336 claims; generic drugs: 8,401 claims; opioid claims: 1,381.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Dan T la $5,096 ($5,096 in general payments such as food, travel and fees) from 24 companies. The largest payer was Abbvie Inc. with $1,291.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 44 | $1,291 |
| Amgen Inc. AMGN | 24 | $657 |
| Novartis Pharmaceuticals Corporation NVS | 20 | $485 |
| UCB, Inc. UCB.BR | 9 | $418 |
| Pfizer Inc. PFE | 15 | $416 |
| GlaxoSmithKline, LLC. GSK | 12 | $352 |
| Alexion Pharmaceuticals, Inc. AZN | 9 | $350 |
| Janssen Biotech, Inc. JNJ | 11 | $277 |
| Radius Health, Inc. | 7 | $222 |
| ANI Pharmaceuticals, Inc. ANIP | 10 | $181 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.